CAR T-cell outcomes by CMV reactivation. (A) 1-year overall mortality, (B) 1-year nonrelapsed mortality, and (C) 1-year progression/relapse rates after CAR T-cell therapy among patients with no CMV reactivation and those with CMV reactivation by day 28. The number of subjects was 95.